Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
Research data
DOI
PMC
 |
Open Access Gold |
|
as soon as is submitted to ZB.
MALDI mass spectrometry imaging—prognostic pathways and metabolites for renal cell carcinomas.
Cancers 14:1763 (2022)
High mass resolution matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is a suitable method for biomarker detection for several tumor entities. Renal cell carcinoma (RCC) is the seventh most common cancer type and accounts for more than 80% of all renal tumors. Prognostic biomarkers for RCC are still missing. Therefore, we analyzed a large, multicenter cohort including the three most common RCC subtypes (clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC)) by MALDI for prognostic biomarker detection. MALDI-Fourier-transform ion cyclotron resonance (FT-ICR)-MSI analysis was performed for renal carcinoma tissue sections from 782 patients. SPACiAL pipeline was integrated for automated co-registration of histological and molecular features. Kaplan–Meier analyses with overall survival as endpoint were executed to determine the metabolic features associated with clinical outcome. We detected several pathways and metabolites with prognostic power for RCC in general and also for different RCC subtypes.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Chromophobe Renal Cell Carcinoma ; Clear-cell Renal Cell Carcinoma ; Mass Spectrometry Imaging ; Metabolomics ; Papillary Renal Cell Carcinoma
ISSN (print) / ISBN
2072-6694
Journal
Cancers
Quellenangaben
Volume: 14,
Issue: 7,
Article Number: 1763
Publisher
MDPI
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Research Unit Analytical Pathology (AAP)
CF Pathology & Tissue Analytics (CF-PTA)
CF Pathology & Tissue Analytics (CF-PTA)
Grants
Deutsche Forschungsgemeinschaft
Deutsche Forschungsgemeinschaft